Long-term use of burosumab for the treatment of tumor-induced osteomalacia

SUMMARY: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral overproduction of FGF-23. Due to local recurrence, we describe the long-term efficacy and safety profile of burosumab, an anti-FGF-23 monoclonal antibody, in a TIO patient after three unsuccessfully surgica...

Descripción completa

Detalles Bibliográficos
Autores principales: Crotti, C., Zucchi, F., Alfieri, C., Caporali, R., Varenna, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361946/
https://www.ncbi.nlm.nih.gov/pubmed/35925260
http://dx.doi.org/10.1007/s00198-022-06516-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361946/
https://www.ncbi.nlm.nih.gov/pubmed/35925260
http://dx.doi.org/10.1007/s00198-022-06516-6

Ejemplares similares